Mark Fletcher - Generex Biotechnology President CEO, General Counsel, Director

GNBTDelisted Stock  USD 0.0001  0.00  0.00%   

CEO

Mr. Mark A. Fletcher, Esquire, is Mr. Fletcher serves as the Companys Executive Vice President General Counsel, Secretary. of Generex Biotechnology Corporationrationration. He served as our President and Chief Executive Officer from September, 2010 through January 17, 2017. Mr. Fletcher served as a member of the Board of Directors from March 2011 through January 17, 2017. Mr. Fletcher was our Executive VicePresident and General Counsel from April, 2003 until September, 2010, and he resumed those roles as of January 17, 2017. Prior to joining Generex, Mr. Fletcher was engaged in the private practice of law as a partner at Goodman and Carr LLP, a leading Toronto law firm. Mr. Fletcher was previously a partner at Brans, Lehun, Baldwin LLP, a law firm in Toronto since 2017.
Age 50
Tenure 7 years
Phone416 364 2551
Webhttps://generex.com/index.html
Fletcher received his LL.B. from the University of Western Ontario in 1989 and was admitted to the Ontario Bar in 1991.

Generex Biotechnology Management Efficiency

The company has return on total asset (ROA) of (0.4384) % which means that it has lost $0.4384 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.7271) %, meaning that it created substantial loss on money invested by shareholders. Generex Biotechnology's management efficiency ratios could be used to measure how well Generex Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 499.66 K in liabilities. Generex Biotechnology has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Generex Biotechnology until it has trouble settling it off, either with new capital or with free cash flow. So, Generex Biotechnology's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Generex Biotechnology sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Generex to invest in growth at high rates of return. When we think about Generex Biotechnology's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 8 records

CEO Age

Marshall LoebEastGroup Properties
62
Charles ProberNETGEAR
53
Yaron RavkaieRadcom
48
David RipsteinRadcom
47
Patrick GoepelAsure Software
62
Peter LauFARO Technologies
44
Michael BurgerFARO Technologies
65
Alexander EdgarovInFintT Acquisition Corp
47
Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. On June 6, 2022, the involuntary petition was approved by the Court. GENEREX BIOTECHNOLOGY operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 15 people. Generex Biotechnology Corp [GNBT] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Generex Biotechnology Leadership Team

Elected by the shareholders, the Generex Biotechnology's board of directors comprises two types of representatives: Generex Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Generex. The board's role is to monitor Generex Biotechnology's management team and ensure that shareholders' interests are well served. Generex Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Generex Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
Eric Hofe, VP, Director and President of Antigen Express, Inc
James Anderson, Independent Director
Jacob Dagan, Executive Vice President Business Development.
Gary Lyman, Independent Director
Mark Prioletti, Independent Interim Director
Andrew Ro, Senior Vice President of Investments, Chief Investment Officer, Director
Kevin Centofanti, Director
Mark Fletcher, President CEO, General Counsel, Director
Terry Thompson, Chief Officer
Craig Eagle, Independent Director
Lawrence Salvo, Director
Marshal Schictman, Executive Vice President General Counsel
Jason Terrell, Chief Scientific Officer, Chief Medical Officer
David Brusegard, COO and Secretary
Omar Gzouli, Independent Interim Director
Andrew Greene, Director
Richard Purcell, Senior Vice President of Research & Drug Development.
Esq CPA, Chief Officer
Joseph Moscato, Chairman of the Board and Presidentident, CEO
Mark Corrao, CFO, Treasurer
Brian McGee, Independent Director
Anthony Dolisi, Chief Officer
Todd Falls, IR Contact Officer
Stephen Fellows, CFO
Michelle Starr, Chief Officer

Generex Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Generex Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Note that the Generex Biotechnology information on this page should be used as a complementary analysis to other Generex Biotechnology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Other Consideration for investing in Generex OTC Stock

If you are still planning to invest in Generex Biotechnology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Generex Biotechnology's history and understand the potential risks before investing.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Transaction History
View history of all your transactions and understand their impact on performance
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.